{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:41:55Z","timestamp":1792636915558,"version":"4.5.0"},"reference-count":64,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022752","name":"MSD Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Patients with gastric cancer, biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) have poor survival outcomes and limited second- or later-line treatment options. Certain drugs targeting vascular endothelial growth factor (VEGF) or programmed cell death protein 1 (PD-1) signaling pathways are currently used in these cancers in specific circumstances; however, there remains a need for novel treatment combinations. LEAP-005 is a multicohort, open-label, phase II study that evaluated lenvatinib (multitargeted inhibitor of tyrosine kinases, including VEGF) plus pembrolizumab (anti\u2013PD-1 monoclonal antibody) in select previously treated solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Participants with previously treated, advanced gastric cancer, BTC, and PDAC were enrolled in cohorts C, F, and G of LEAP-005, respectively, and received lenvatinib 20 mg\/day orally plus pembrolizumab 200 mg i.v. every 3 weeks. Primary endpoints were objective response rate (ORR) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 99, 102, and 103 total participants enrolled in cohorts C, F, and G, respectively, median times from first dose of study treatment to data cutoff (February 6, 2023) were 23.7, 24.2, and 19.5 months. ORRs (95% confidence interval) by blinded independent central review were 15.2% (8.7%\u201323.8%) in cohort C, 17.6% (10.8%\u201326.4%) in cohort F, and 7.8% (3.4%\u201314.7%) in cohort G. Grade 3 to 5 treatment-related adverse events occurred in 54.5% of participants in cohort C, and grade 3 to 4 (no grade 5) occurred in 60.8% and 59.2% of participants in cohorts F and G, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In the phase II LEAP-005 study, lenvatinib plus pembrolizumab showed modest antitumor activity and a manageable safety profile in participants with previously treated gastrointestinal-related cancers. Exploratory analyses in participants with BTC indicated higher ORRs in participants with targetable alterations versus those without.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0018","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:14:16Z","timestamp":1772140456000},"page":"673-686","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3240-729X","authenticated-orcid":false,"given":"Mariano","family":"Ponz-Sarvis\u00e9","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology and Program in Solid Tumors, Cancer Center Cl\u00ednica Universidad de Navarra (CCUN), Cima-Universidad de Navarra, Pamplona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-4531","authenticated-orcid":false,"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[{"name":"2Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-2529","authenticated-orcid":false,"given":"Carlos A.","family":"Gomez-Roca","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/014hxhm89","id-type":"ROR","asserted-by":"publisher"}],"name":"Institut Universitaire du Cancer de Toulouse Oncopole 3 , Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-7322","authenticated-orcid":false,"given":"Laura","family":"Ortega Mor\u00e1n","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4946-9114","authenticated-orcid":false,"given":"Sanjeev","family":"Gill","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01wddqe20","id-type":"ROR","asserted-by":"publisher"}],"name":"The Alfred Hospital 5 , Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-4962","authenticated-orcid":false,"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[{"name":"6Medical Oncology, Fondazione Policlinico A Gemelli IRCCS, Rome, Italy."},{"name":"7Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5380-4948","authenticated-orcid":false,"given":"Ravit","family":"Geva","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04nd58p63","id-type":"ROR","asserted-by":"publisher"}],"name":"Tel Aviv Sourasky Medical Center 8 , Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3924-286X","authenticated-orcid":false,"given":"Esma","family":"Saada-Bouzid","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05hmfw828","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre Antoine Lacassagne 9 Early Phase Trial Unit, , Nice, France."},{"name":"10Laboratory of Translational Research, C\u00f4te d\u2019Azur University, Nice, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05d538656","id-type":"ROR","asserted-by":"publisher"}],"name":"Humanitas Research Hospital 11 IRCCS, , Milan, Italy."},{"name":"12Department of Biomedical Sciences, Humanitas University, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-1997","authenticated-orcid":false,"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[{"name":"13Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-4584","authenticated-orcid":false,"given":"Daniel","family":"Heudobler","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01226dv09","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Regensburg 14 , Regensburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3483-716X","authenticated-orcid":false,"given":"Corina E.","family":"Dutcus","sequence":"additional","affiliation":[{"name":"15Eisai Inc., Nutley, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5621-9138","authenticated-orcid":false,"given":"Chinyere E.","family":"Okpara","sequence":"additional","affiliation":[{"name":"16Eisai Ltd., Hatfield, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3095-8612","authenticated-orcid":false,"given":"Razi","family":"Ghori","sequence":"additional","affiliation":[{"name":"17Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0544-6094","authenticated-orcid":false,"given":"Yiwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"17Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8271-8566","authenticated-orcid":false,"given":"Amir","family":"Vajdi","sequence":"additional","affiliation":[{"name":"17Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0059-836X","authenticated-orcid":false,"given":"E.J.","family":"Dettman","sequence":"additional","affiliation":[{"name":"17Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7975-0016","authenticated-orcid":false,"given":"Fan","family":"Jin","sequence":"additional","affiliation":[{"name":"17Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-7675","authenticated-orcid":false,"given":"Roman","family":"Groisberg","sequence":"additional","affiliation":[{"name":"17Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-080X","authenticated-orcid":false,"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/020rzx487","id-type":"ROR","asserted-by":"publisher"}],"name":"Sheba Medical Center 18 Ella Lemelbaum Institute for Immuno-Oncology, , Ramat Gan, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026032601382178800_bib1","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.3390\/ijms21114012","article-title":"Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies","volume":"21","author":"Machlowska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026032601382178800_bib2","doi-asserted-by":"crossref","first-page":"100503","DOI":"10.1016\/j.esmoop.2022.100503","article-title":"Advances in the systemic treatment of therapeutic approaches in biliary tract cancer","volume":"7","author":"Mirallas","year":"2022","journal-title":"ESMO Open"},{"key":"2026032601382178800_bib3","doi-asserted-by":"crossref","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic cancer: a review of current treatment and novel therapies","volume":"36","author":"Kolbeinsson","year":"2023","journal-title":"J Invest Surg"},{"key":"2026032601382178800_bib4","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines)","author":"National Comprehensive Cancer Network (NCCN)","year":"2025","journal-title":"Gastric Cancer. Version 3.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network"},{"key":"2026032601382178800_bib5","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines). Biliary Tract Cancers","author":"National Comprehensive Cancer Network (NCCN)","year":"2025","journal-title":"Version 2.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network"},{"key":"2026032601382178800_bib6","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines). Pancreatic adenocarcinoma. Version 2.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network","author":"National Comprehensive Cancer Network (NCCN)","year":"2025"},{"key":"2026032601382178800_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"2026032601382178800_bib8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon-2020-0937","article-title":"The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors","volume":"17","author":"Taylor","year":"2021","journal-title":"Future Oncol"},{"key":"2026032601382178800_bib9","article-title":"Full prescribing information","author":"Keytruda (pembrolizumab)","year":"2024"},{"key":"2026032601382178800_bib10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"2026032601382178800_bib11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"2026032601382178800_bib12","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2026032601382178800_bib13","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2026032601382178800_bib14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026032601382178800_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Invest New Drugs"},{"issue":"15_suppl","key":"2026032601382178800_bib16","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1200\/JCO.2021.39.15_suppl.4128","article-title":"Randomized multicenter phase Ib\/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer","volume":"39","author":"Rahma","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026032601382178800_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026032601382178800_bib18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026032601382178800_bib19","volume-title":"Eisai Inc. US Food & Drug Administration","author":"Lenvima (lenvatinib)","year":"2025"},{"key":"2026032601382178800_bib20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","article-title":"Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies","volume":"82","author":"Adachi","year":"2022","journal-title":"Cancer Res"},{"key":"2026032601382178800_bib21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","article-title":"Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results","volume":"20","author":"Ueno","year":"2020","journal-title":"BMC Cancer"},{"key":"2026032601382178800_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/jcm9030675","article-title":"Combining immune checkpoint inhibitors with anti-angiogenic agents","volume":"9","author":"Ciciola","year":"2020","journal-title":"J Clin Med"},{"key":"2026032601382178800_bib23","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"key":"2026032601382178800_bib24","doi-asserted-by":"crossref","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"2026032601382178800_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"2026032601382178800_bib26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026032601382178800_bib27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026032601382178800_bib28","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026032601382178800_bib29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026032601382178800_bib30","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(20)30271-0","article-title":"Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial","volume":"21","author":"Kawazoe","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026032601382178800_bib31","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026032601382178800_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1208\/s12248-020-00525-1","article-title":"Keytruda and PD-L1: a real-world example of co-development of a drug with a predictive biomarker","volume":"23","author":"Emancipator","year":"2020","journal-title":"AAPS J"},{"key":"2026032601382178800_bib33","doi-asserted-by":"crossref","first-page":"e003091","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026032601382178800_bib34","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-21-3329","article-title":"Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types","volume":"28","author":"Cristescu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12_Supplement","key":"2026032601382178800_bib35","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1158\/1538-7445.AM2022-5136","article-title":"Abstract 5136: development of a novel gene expression signature that correlates with intratumor microvessel density and antitumor activity of lenvatinib","volume":"82","author":"Kuronishi","year":"2022","journal-title":"Cancer Res"},{"key":"2026032601382178800_bib36","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2026032601382178800_bib37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026032601382178800_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026032601382178800_bib39","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026032601382178800_bib40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00280-012-2027-3","article-title":"A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil\/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy","volume":"71","author":"Sym","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026032601382178800_bib41","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2013a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer"},{"key":"2026032601382178800_bib42","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026032601382178800_bib43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdh007","article-title":"Phase II study of irinotecan and 5-fluorouracil\/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma","volume":"15","author":"Assersohn","year":"2004","journal-title":"Ann Oncol"},{"key":"2026032601382178800_bib44","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026032601382178800_bib45","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer"},{"key":"2026032601382178800_bib46","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10120-019-01034-7","article-title":"A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data","volume":"23","author":"Chen","year":"2020","journal-title":"Gastric Cancer"},{"key":"2026032601382178800_bib47","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"key":"2026032601382178800_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026032601382178800_bib49","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026032601382178800_bib50","doi-asserted-by":"crossref","first-page":"1109292","DOI":"10.3389\/fimmu.2023.1109292","article-title":"Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"2026032601382178800_bib51","first-page":"1026","article-title":"Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"2026032601382178800_bib52","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/j.annonc.2024.08.053","article-title":"44P Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: the COMBATBIL imCORE trial","volume":"35","author":"Ponz-Sarvise","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"2026032601382178800_bib53","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.2024.42.16_suppl.4095","article-title":"Abstract: the safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer","volume":"42","author":"Ying","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026032601382178800_bib54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.36922\/EJMO025120063","article-title":"Meta-analysis of the prognostic value of KRAS and TP53 mutations in cholangiocarcinoma","volume":"9","author":"Xu","year":"2025","journal-title":"Eurasian J Med Oncol"},{"key":"2026032601382178800_bib55","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41416-025-03011-7","article-title":"Alterations in genomic features and the tumour immune microenvironment predict immunotherapy outcomes in advanced biliary tract cancer patients","volume":"132","author":"Huang","year":"2025","journal-title":"Br J Cancer"},{"key":"2026032601382178800_bib56","doi-asserted-by":"crossref","first-page":"17562848231170484","DOI":"10.1177\/17562848231170484","article-title":"The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation","volume":"16","author":"Jeong","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"2026032601382178800_bib57","doi-asserted-by":"crossref","first-page":"e003214","DOI":"10.1136\/jitc-2021-003214","article-title":"Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes","volume":"9","author":"Chen","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026032601382178800_bib58","doi-asserted-by":"crossref","first-page":"e2400263","DOI":"10.1200\/PO.24.00263","article-title":"KRAS variants are associated with survival outcomes and genomic alterations in biliary tract cancers","volume":"8","author":"Gelfer","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026032601382178800_bib59","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.3748\/wjg.v27.i17.1847","article-title":"Pancreatic adenocarcinoma: beyond first line, where are we?","volume":"27","author":"Cherri","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2026032601382178800_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.hbpd.2018.03.007","article-title":"The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: a meta-analysis","volume":"17","author":"Gao","year":"2018","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2026032601382178800_bib61","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","article-title":"Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer","volume":"26","author":"Wainberg","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026032601382178800_bib62","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"2026032601382178800_bib63","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40885-022-00197-3","article-title":"Risks and management of hypertension in cancer patients undergoing targeted therapy: a review","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Hypertens"},{"key":"2026032601382178800_bib64","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2271","article-title":"LEAP-005: phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","volume":"31","author":"Lwin","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0018\/3743557\/crc-26-0018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/673\/3753687\/crc-26-0018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/673\/3753687\/crc-26-0018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:38:33Z","timestamp":1774503513000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/3\/673\/776487\/Lenvatinib-plus-Pembrolizumab-for-Patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0018","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31858071","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858077","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858134","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858122","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858110","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858089","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858095","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858083","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858140","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858119","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858107","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858149","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858137","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858125","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858113","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858080","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858092","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858101","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858098","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858143","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858131","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858086","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858074","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858128","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858104","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858116","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31858146","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8383530","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}